



PTO/SB/08A (08-03)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/688,299
				Filing Date	October 16, 2003
				First Named Inventor	Finn, John
				Art Unit	Not yet assigned 1636
Examiner Name	Not yet assigned Guy Guidry				
Sheet	1	of	2	Attorney Docket Number	020801-000320US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number ⁴	Kind Code ⁵ (if known)				
GG	AA	WO	97/41243	A2	11/06/1997	University of Pittsburgh		<input type="checkbox"/>
	AB	WO	00/58488	A2, A3	10/05/2000	Invirogen Corporation		<input type="checkbox"/>
L	AC	WO	01/15511	A2	03/08/2001	University of Pittsburgh of the Commonwealth System of Higher Education		<input type="checkbox"/>

Examiner Signature		Date Considered	3/1/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60141805 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/688,299		
		Filing Date	October 16, 2003		
		First Named Inventor	Finn, John		
		Art Unit	Not yet assigned 1636		
		Examiner Name	Not yet assigned Guy Guidry		
Sheet	2	of	2	Attorney Docket Number	020801-000320US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GG	AD	BENNETT, R.P. and Dalby, B.; "Protein delivery using VP22"; <u>Nature Biotechnology</u> ; January 2002; p. 20; Vol. 20.	
	AE	BRISSON, M. et al.; "A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes"; <u>Gene Therapy</u> ; 1999; pp. 263-270; Vol. 6.	
	AF	CHEN, X. et al.; "A self-initiating eukaryotic transient gene expression system based on cotransfection of bacteriophage T7 RNA polymerase and DNA vectors containing an T7 autophage"; <u>Nucleic Acids Research</u> ; 1994; pp. 2114-2120; Vol. 22, No. 11.	
	AG	DEROSSI et al.; "Trojan peptides: the penetratin system for intracellular delivery"; <u>Trends in Cell Biology</u> ; 1998; pp. 84-87; Vol. 8, No. 2.	
	AH	ELROY-STEIN et al.; "Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells"; <u>Proc. Natl. Acad. Sci. U.S.A.</u> ; 1990; pp. 6743-6747; Vol. 87, No. 17	
	AI	FINN, J. et al.; "The development and comparison of three cytoplasmic expression systems based on the T7, T3 and SP6 phage RNA polymerase proteins"; <u>ASGT Fourth Annual Meeting</u> ; May 30-June 3, 2001; Seattle, Washington.	
	AJ	GAO, X. and Huang, L.; "Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes"; <u>Nucleic Acids Research</u> ; 1993; pp. 2867-2872; Vol. 21, No. 12.	
	AK	LINDGREN et al.; "Cell-penetrating peptides"; <u>Trends In Pharmacological Sciences</u> ; 2000; pp. 99-103; Vol. 21, No. 3	

Examiner Signature		Date Considered	3/1/06
--------------------	--	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A&B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/688,299
Filing Date	October 16, 2003
First Named Inventor	Finn, John
Art Unit	Not yet assigned 1636
Examiner Name	Not yet assigned Guy Guidry
Attorney Docket Number	020801-000320US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GG	B1	US-6,586,410 B1	07-01-2003	Jeffery Wheeler, et al.	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
GG	B2	WO	02/088370	A2	11-07-2002	Protiva Biotherapeutics		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GG	B3	FINN, J., et al., "An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression," <u>Gene Therapy</u> , 2004, Vol. 11, pp. 276-283.	
GG	B4	LI, J., et al., "Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice," <u>Cancer Gene Therapy</u> , 2000, Vol. 7, No. 11, pp. 1448-1455.	

Examiner
SignatureDate
Considered

P/1/06

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.